Here are the 10-K annual reports from Iovance Biotherapeutics, Inc. (IOVA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.
Iovance Biotherapeutics is a commercial-stage biotech company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its first commercial product, Amtagvi (lifileucel), is approved in the U.S. and Canada for previously treated advanced melanoma and is given with lymphodepletion and Proleukin.
The company estimates Amtagvi could address over 30,000 advanced melanoma patients annually and is pursuing additional approvals in the UK, Australia, Switzerland and the EU. A Phase 3 trial (TILVANCE-301) is testing lifileucel plus pembrolizumab in frontline melanoma, while the IOV-LUN-202 registrational trial targets previously treated advanced non-squamous NSCLC.
Iovance has centralized manufacturing at its FDA‑approved Iovance Cell Therapy Center in Philadelphia, which has capacity for more than 5,000 patients per year and has produced TIL therapies for over 1,500 patients. As of February 13, 2026, there were 411,961,607 shares of common stock outstanding.